Abstract

Interleukin-1β (IL-1β) is activated by inflammasome-associated caspase-1 in rare autoinflammatory conditions and in a variety of other inflammatory diseases. Therefore, IL-1β activity must be fine-tuned to enable anti-microbial responses whilst limiting collateral damage. Here, we show that precursor IL-1β is rapidly turned over by the proteasome and this correlates with its decoration by K11-linked, K63-linked and K48-linked ubiquitin chains. The ubiquitylation of IL-1β is not just a degradation signal triggered by inflammasome priming and activating stimuli, but also limits IL-1β cleavage by caspase-1. IL-1β K133 is modified by ubiquitin and forms a salt bridge with IL-1β D129. Loss of IL-1β K133 ubiquitylation, or disruption of the K133:D129 electrostatic interaction, stabilizes IL-1β. Accordingly, Il1bK133R/K133R mice have increased levels of precursor IL-1β upon inflammasome priming and increased production of bioactive IL-1β, both in vitro and in response to LPS injection. These findings identify mechanisms that can limit IL-1β activity and safeguard against damaging inflammation.

Hyperactivation of inflammasome-induced IL-1β can cause immunopathology and is a feature of autoinflammatory diseases. Here, the authors show how ubiquitination of IL-1β limits its activity by targeting it for proteasomal degradation and preventing its cleavage by caspase-1.

Details

Title
The ubiquitylation of IL-1β limits its cleavage by caspase-1 and targets it for proteasomal degradation
Author
Vijayaraj, Swarna L 1 ; Feltham, Rebecca 1   VIAFID ORCID Logo  ; Rashidi Maryam 1 ; Frank, Daniel 1 ; Liu Zhengyang 2   VIAFID ORCID Logo  ; Simpson, Daniel S 1 ; Ebert, Gregor 1   VIAFID ORCID Logo  ; Vince Angelina 2 ; Herold, Marco J 1 ; Kueh, Andrew 1 ; Pearson, Jaclyn S 3   VIAFID ORCID Logo  ; Dagley, Laura F 1   VIAFID ORCID Logo  ; Murphy, James M 1   VIAFID ORCID Logo  ; Webb, Andrew I 1   VIAFID ORCID Logo  ; Lawlor, Kate E 4   VIAFID ORCID Logo  ; Vince, James E 1   VIAFID ORCID Logo 

 The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7); University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
 The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) 
 Hudson Institute of Medical Research, Centre for Innate Immunity and Infectious Diseases, Clayton, Australia (GRID:grid.452824.d); Monash University, Department of Microbiology, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Department of Molecular and Translational Science, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857) 
 The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7); University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Hudson Institute of Medical Research, Centre for Innate Immunity and Infectious Diseases, Clayton, Australia (GRID:grid.452824.d); Monash University, Department of Molecular and Translational Science, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2525230578
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.